Search research articles
Contact Us
Filters
Showing results (451-460 of 522) with videos related to
Page
of 53
Sort By:
JAMA Oncology
|
December 14, 2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial
Dejan Juric, Filip Janku, Jordi Rodón, et al.
British Journal of Cancer
|
March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
S P Blagden, L R Molife, A Seebaran, et al.
Cancer
|
October 18, 2018
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer
Toby A Eyre, Graham P Collins, Avinash Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
M R Middleton, J J Grob, N Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
D S Boss, G K Schwartz, M R Middleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2022
VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface
Vinton W T Cheng, Nicholas de Pennington, Rasheed Zakaria, et al.
Scientific Reports
|
May 10, 2018
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
T P MacGregor, R Carter, R S Gillies, et al.
Journal of the National Cancer Institute
|
March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma
Christy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Cancers
|
January 13, 2019
The Circulating Transcriptome as a Source of Biomarkers for Melanoma
Carla Solé, Daniela Tramonti, Maike Schramm, et al.
BMC Cancer
|
May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Stéphane Dalle, Laurent Mortier, Pippa Corrie, et al.
Page
of 53
Search research articles
Search
Showing results (451-460 of 522) with videos related to
Sort By:
Page
of 53
JAMA Oncology
|
December 14, 2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial
Dejan Juric, Filip Janku, Jordi Rodón, et al.
British Journal of Cancer
|
March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
S P Blagden, L R Molife, A Seebaran, et al.
Cancer
|
October 18, 2018
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer
Toby A Eyre, Graham P Collins, Avinash Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
M R Middleton, J J Grob, N Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
D S Boss, G K Schwartz, M R Middleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2022
VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface
Vinton W T Cheng, Nicholas de Pennington, Rasheed Zakaria, et al.
Scientific Reports
|
May 10, 2018
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma
T P MacGregor, R Carter, R S Gillies, et al.
Journal of the National Cancer Institute
|
March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma
Christy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Cancers
|
January 13, 2019
The Circulating Transcriptome as a Source of Biomarkers for Melanoma
Carla Solé, Daniela Tramonti, Maike Schramm, et al.
BMC Cancer
|
May 30, 2021
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Stéphane Dalle, Laurent Mortier, Pippa Corrie, et al.
Page
of 53